The phase 4 study is known as IXORA-R. This study was a head to head study between Taltz and Tremfya. There were a total of 1,027 patients with moderate to severe plaque psoriasis. The primary ...

Eli Lilly courts physicians with blockbuster-topping Taltz data In the June data presentation, 36% of patients treated with Taltz hit both markers at 24 weeks, topping Humira, which saw only 28% ...

The minute-long commercial, featuring lots of bare shoulders, midriffs and swimsuits, promotes a new drug by Eli Lilly and Co. called Taltz that treats red, scaly patches of skin caused by ...

INDIANAPOLIS, Aug. 13, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today Taltz ® (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 ...

Eli Lilly's Taltz and Novartis' Cosentyx have been jockeying for IL-17 inhibitor supremacy with back-and-forth FDA approvals for years. But in the race for a fourth indication, Taltz has come out ...

Eli Lilly announced that the Food and Drug Administration (FDA) has approved Taltz (ixekizumab) injection for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for ...

The new formulation significantly reduced injection site pain compared with the original. A new citrate-free formulation of Taltz ® (ixekizumab) has been made available by Eli Lilly. Taltz, an ...

INDIANAPOLIS, May 22, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label update for Taltz ® (ixekizumab ...

That showed Taltz was able to work well and achieve the primary goal in both studies. The first late-stage study, known as COAST-V, evaluated patients who didn't take any antirheumatic drug ...

Drugmaker Eli Lilly & Co (LLY) said that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (BLA) for its Taltz injection used for the treatment ...